Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era

Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangaraju, Pugazhenthan, Venkatesan, Nanditha, Thangaraju, Eswaran, Venkatesan, Sajitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519855/
https://www.ncbi.nlm.nih.gov/pubmed/33015549
http://dx.doi.org/10.1007/s42399-020-00550-3
Descripción
Sumario:Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19 yet. The limited-to-no experience of the Indian health workforce with the drug urged us to conduct a situational analysis in the pre-COVID era to analyse the degree of use of the drug and the indications for which it has been employed.

Ejemplares similares